Search Results

Clinical Focus | August 2019

Parting Words from Jerry Bagel, MD

The psoriasis treatment landscape has changed dramatically during this editor’s tenure.

Jerry Bagel, MD, FAAD

Clinical Focus | May 2019

A Closer Look at Skyrizi

The newest IL-23 blocker for psoriasis may prove to be a blockbuster, according to analysts.

Jerry Bagel, MD, FAAD

Clinical Focus | February 2019

Biologics in Psoriasis: The Next Generation

Get familiar with the IL-23 monoclonal antibodies.

Jerry Bagel, MD, FAAD

Clinical Focus | January 2019

What's on the Horizon for Common Skin Diseases?

Experts share their psoriasis, acne, and AD wish lists for 2019.

Jerry Bagel, MD, FAAD; Peter A. Lio, MD; and Joshua Zeichner, MD

Clinical Focus | October 2018

First, Do No Harm

Weighing the data on Cimzia during pregnancy and lactation.

Jerry Bagel, MD, FAAD

Clinical Focus | July 2018

New Therapeutic Options for the Treatment of Psoriatic Arthritis: IL-17 Blockers

Are TNF inhibitors still the gold standard for PsA?

Jerry Bagel, MD, FAAD

Clinical Focus | February 2018

It's Time to Get Serious About Scalp Psoriasis Treatment

Largely due to adherence issues, topical treatments don't work for many scalp psoriasis patients.

Jerry Bagel, MD, FAAD

Clinical Foucs | August 2017

What Is Really Going On In Psoriatic Skin?

Take a walk through the pathogenesis of psoriasis to understand how new and emerging therapies may offer benefit.

Jerry Bagel, MD, FAAD

Clinical Focus | July 2017

Psoriasis Wish List

Clinical thought leaders share what they hope for to improve treatment in the future.

With Jerry Bagel, MD; Seemal R. Desai, MD, FAAD; Adam Friedman, MD, FAAD; and Gary Goldenberg, MD

July 2016

Physician Spotlight: Jerry Bagel, MD, FAAD

Director, Psoriasis Treatment Center of Central New Jersey

Physician Focus | June 2012

Jerry Bagel, MD, FAAD